COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00760708
Recruitment Status : Terminated (Persantine is no longer being used at UCHC for pharmacological stress testing)
First Posted : September 26, 2008
Last Update Posted : May 14, 2019
United States Department of Defense
Information provided by (Responsible Party):
Bruce Liang, UConn Health

Brief Summary:
Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosine is a naturally occurring substance in the body that can increase blood flow. Adenosine is normally removed from the bloodstream by an adenosine transporter, which is a protein that takes up adenosine from the blood into cells. The increase in adenosine levels in the blood is variable, and the cause for this variability is unknown. A mutation for this transporter gene may contribute to this variability, and may alter its function. Thus, the purpose of this study is to determine the relationship between the mutation and the transporter function.

Condition or disease
Ischemia Coronary Disease

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 221 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
Study Start Date : September 2005
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Adenosine

undergoing persantine stress test

Primary Outcome Measures :
  1. To determine functional significance and association of these polymorphisms with the ability of persantine to inhibit uridine (uridine uses the same transporter) uptake and platelet aggregation. [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Investigators will study the association of these polymorphisms with any clinical characteristics such as the incidence of MI, acute coronary syndrome, coronary bypass or stenting procedures. These clinical outcomes are considered secondary endpoints. [ Time Frame: 2 years ]

Biospecimen Retention:   Samples With DNA
whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects undergoing a Persantine nuclear stress test for medically-indicated reasons. There are no control subjects.

Inclusion Criteria:

  • Subjects with or without coronary artery disease undergoing a Persantine nuclear stress test

Exclusion Criteria:

  • Oral persantine use within 24 hours
  • Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
  • Active asthma or bronchospasm
  • Those with end-stage liver disease such as cirrhosis or active hepatitis such as > 5 fold liver enzyme elevation will not be included
  • Anemia (Hct < 30)
  • Myocardial infarction within 30 days
  • Severe left ventricular dysfunction (EF < 30%)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00760708

Layout table for location information
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06032
Sponsors and Collaborators
UConn Health
United States Department of Defense
Layout table for investigator information
Principal Investigator: Bruce T Liang, MD UConn Health
Layout table for additonal information
Responsible Party: Bruce Liang, Professor of Medicine, Director Pat and Jim Calhoun Cardiovascular Center, UConn Health Identifier: NCT00760708    
Other Study ID Numbers: 02-115-1
Proposal Number 04156012
Award NumberW81XWH-05-1-0060
First Posted: September 26, 2008    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019
Keywords provided by Bruce Liang, UConn Health:
myocardial ischemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases